Agile Therapeutics Inc (AGRX) Gross Profit Margin starting from the second quarter 2024 to second quarter 2023, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Agile Therapeutics Inc  (AGRX)


Agile Therapeutics Inc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AGRX Gross Profit Margin (Jun 30 2024)
Q2 		(Mar 31 2024)
Q1 		(Dec 31 2023)
Q4 		(Sep 30 2023)
Q3 		(Jun 30 2023)
Q2
Y / Y Revenue Change -2.23 %
Seq. Revenue Change 0.87 %
Revenue In Millions $5.08
Gross Profit Margin 80.31 %
Gross Profit Margin Total Ranking # 675
Gross Profit In Millions $4.08
Y / Y Gross Profit Change 27.66 %
Seq. Gross Profit Change 1.09 %


Commenting Second Quarter 2024 Gross Profit Margin
Agile Therapeutics Inc Gross Profit grew by 1.09 % in Q2 sequentially to 4 millions, while Revenue increased by 0.87 %, this led to improvement in the company's Gross Profit Margin to 80.31 % a new company high.


Observing second quarter 2024 results within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 675, from total ranking in the previous quarter at 681.
Learn about Gross Margin
AGRX's Gross Profit Margin second quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 64
Healthcare Sector # 114
Overall # 666

Gross Profit Margin Statistics
High Average Low
80.31 % 51.72 % 3.38 %
(Jun 30 2024)   (Jun 30 2021)


AGRX Gross Income Trends • More of AGRX's Profitabilty Ratios • AGRX Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
AGRX's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
AGRX's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for AGRX's Competitors
Gross Profit Margin Profit Margin for Agile Therapeutics Inc's Suppliers
Gross Profit Margin Profit Margin for AGRX's Customers

You may also want to know
AGRX's Annual Growth Rates AGRX's Profitability Ratios AGRX's Asset Turnover Ratio AGRX's Dividend Growth
AGRX's Roe AGRX's Valuation Ratios AGRX's Financial Strength Ratios AGRX's Gross Profit Growth
AGRX's Roa AGRX's Inventory Turnover Ratio AGRX's Growth Rates AGRX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2024, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2024 MRQ Gross ProfitJun 30 2024 MRQ Revenue
Zai Lab Limited  99.92 %$ 100.419  Millions$ 100.504  Millions
Abvc Biopharma Inc   99.84 %$ 0.117  Millions$ 0.117  Millions
Corcept Therapeutics Inc  98.46 %$ 161.272  Millions$ 163.796  Millions
Macrogenics Inc   98.37 %$ 10.621  Millions$ 10.797  Millions
Adc Therapeutics Sa  98.35 %$ 17.122  Millions$ 17.410  Millions
Uniqure N v   97.90 %$ 10.892  Millions$ 11.126  Millions
Therapeuticsmd Inc   97.86 %$ 0.229  Millions$ 0.234  Millions
Gyre Therapeutics Inc   96.95 %$ 24.455  Millions$ 25.225  Millions
Karyopharm Therapeutics Inc   96.58 %$ 41.321  Millions$ 42.786  Millions
Travere Therapeutics Inc   96.19 %$ 52.055  Millions$ 54.116  Millions
Emmaus Life Sciences Inc   95.52 %$ 5.136  Millions$ 5.377  Millions
Avadel Pharmaceuticals Plc  95.09 %$ 38.716  Millions$ 40.716  Millions
Vanda Pharmaceuticals Inc   94.59 %$ 47.741  Millions$ 50.474  Millions
Blueprint Medicines Corporation  94.50 %$ 130.564  Millions$ 138.157  Millions
Bioxcel Therapeutics Inc   94.38 %$ 1.042  Millions$ 1.104  Millions
Innoviva Inc   93.51 %$ 121.982  Millions$ 130.454  Millions
Regeneron Pharmaceuticals Inc   92.73 %$ 3,289.300  Millions$ 3,547.100  Millions
Acadia Pharmaceuticals Inc   92.47 %$ 223.733  Millions$ 241.963  Millions
Rigel Pharmaceuticals Inc  92.38 %$ 34.034  Millions$ 36.841  Millions
Silo Pharma Inc  91.91 %$ 0.017  Millions$ 0.018  Millions
Amicus Therapeutics inc   91.30 %$ 115.408  Millions$ 126.408  Millions
Marinus Pharmaceuticals Inc   90.88 %$ 7.321  Millions$ 8.056  Millions
Ocular Therapeutix Inc   90.82 %$ 14.932  Millions$ 16.441  Millions
Axsome Therapeutics Inc   90.76 %$ 79.111  Millions$ 87.166  Millions
Urogen Pharma Ltd   90.75 %$ 19.619  Millions$ 21.619  Millions
Optinose Inc   90.33 %$ 18.509  Millions$ 20.490  Millions
Axim Biotechnologies Inc   90.02 %$ 0.016  Millions$ 0.017  Millions
Lexicon Pharmaceuticals Inc   89.92 %$ 1.481  Millions$ 1.647  Millions
Rhythm Pharmaceuticals Inc   89.87 %$ 26.131  Millions$ 29.078  Millions
Alnylam Pharmaceuticals Inc   89.80 %$ 592.554  Millions$ 659.825  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.